Skip to content

Effect of a proprietary potato protease inhibitor on satiety, cholecystokinin concentration, weight loss and cognitive status in overweight individuals with increased waist circumference".

Effect of a proprietary potato protease inhibitor on satiety, cholecystokinin concentration, weight loss and cognitive status in overweight individuals with increased waist circumference". - /

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00015821
Enrollment
52
Registered
2018-11-19
Start date
2008-08-04
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E66

Interventions

Group 1: Individually tailored protein-rich reduction diet with 3 main meals over 20 weeks. One capsule (PI2 inhibitor, 150 mg) with 200 ml water is taken one hour before lunch and dinner. The degree

Sponsors

Herbalife Nutrition
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 25 - 55 years, women or men. Negative pregnancy test. Surgical sterilization, menopause for at least 6 months or contraception by spiral or hormones. BMI 25 - 40 kg/m² and waist circumference women > 80 cm, men > 94 cm Health, determined by anamnesis, clinical examination and laboratory tests (blood count, Na, K, Ca, urea, creatinine, uric acid, ALT, AST, AP, GT, bilirubin, basal TSH, triglycerides, total cholesterol, HDL cholesterol, blood sugar, serum insulin, HbA1c and urine status). Stable body weight in the last 3 months (fluctuation <2%). Willingness to complete visual analogue scale (VAS) four times on 5 days and at test meals. Willingness to prepare a diet protocol 4 times on 3 days. Willingness to take blood samples before and after a test meal both at the beginning of the study and after 10 weeks. To have been informed that normal care is provided even if participation in the study is not desired. Tolerance of the test meal. Written consent to participate in the study

Exclusion criteria

Exclusion criteria: BMI > 40 kg/m². Body weight fluctuations of > 2% in the last month. Estimated energy requirement / day 10 kg in the last 6 months. Surgical measures due to obesity. Diabetes mellitus, CVD, kidney or liver disease, psychiatric diseases. Abnormal laboratory parameters (serum creatinine, ALT, AST, bilirubin, TSH, triglycerides > 5.0 mol/l, cholesterol > 9.0 mmol/l). Desire to have children, breastfeeding mothers. Taking medication for weight loss or medication for diseases whose course cannot yet be estimated. Smokers, alcohol consumption > 2 drinks/day Allergies to potatoes, Panax ginseng or roseroot. Drug and medication abuse hypothyroidism that is not already treated with thyroid hormone Patients with pacemakers, metal plates, piercing that cannot be removed. Taking test substances in the last 8 weeks. Intolerance of the test meal.

Design outcomes

Primary

MeasureTime frame
Satiety - after 0, 10 and 20 weeks Measuring instrument is a questionnaire according to Flint (Int J Obes Relat Metab Disord 2000;24(1):38-48)

Secondary

MeasureTime frame
Cholecystokinin, glucagon-like peptide 1, ghrelin, insulin. Methods: Radioimmunoassay, Elisa Kit Time of measurement: Day 1, week 0 and day 1, 10th week, both before and after taking a test meal. Anthropometric measurement: Percentage change in weight, waist circumference (scale and tape measure), blood pressure (blood pressure monitor measurement), triglycerides, HDL cholesterol (routine clinical chemistry methods). Time week 0,10, 20

Countries

Germany

Contacts

Public ContactMarion Flechtner-Mors

Universitätsklinikum Ulm

sport.medizin@uniklinik-ulm.de073150045350

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026